Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Allogene announces $175 million public stock offering
-
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
-
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
-
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
-
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
-
Allogene Therapeutics Announces Participation in March Investor Conference
-
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
-
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
-
Allogene Therapeutics Announces Participation in November Investor Conferences
-
Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.
-
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
-
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
-
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
-
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
-
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
-
Cowen Reiterates Outperform Rating on Allogene (ALLO), "We Recommend Accumulating ALLO Shares"
-
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
-
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
-
Allogene (ALLO) Named Best 2022 Idea at Cowen
-
Cowen Lists Multiple 'Best Ideas For 2022' (ABNB) (RL) (CHPT) (LNG) (SWCH) (AMZN) (IIVI) (PATH) (CFLT) (ALLO)
-
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
-
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
-
Cowen Assumes Allogene (ALLO) at Outperform
-
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
-
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
-
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
-
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
-
Allogene Therapeutics (ALLO) Prices 11.7M Share Common Offering at $47/Sh
-
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
-
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
-
Allogene Therapeutics (ALLO) Announces Proposed $450M Common Offering
-
Allogene Therapeutics Announces Commencement of Public Offering of Common Stock
-
Allogene Therapeutics Announces Commencement of Public Offering of Common Stock
-
Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule
-
Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule
-
Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule
-
Allogene Therapeutics Announces February and March 2019 Investor Conference Schedule
-
Allogene Therapeutics Announces February and March 2019 Investor Conference Schedule
-
Cowen Starts Allogene (ALLO) at Outperform
-
Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Allogene Therapeutics (ALLO) IPO Opens Up 22%

